Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
2008 3
2009 3
2015 1
2017 5
2018 3
2019 5
2020 2
2021 4
2022 4
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, Cambon-Thomsen A, Cecchin E, Cheung KC, Deneer VH, Dupui M, Ingelman-Sundberg M, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Mitropoulou C, Rial-Sebbag E, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, Dávila Fajardo CL, Dolžan V, Patrinos GP, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. Swen JJ, et al. Lancet. 2023 Feb 4;401(10374):347-356. doi: 10.1016/S0140-6736(22)01841-4. Lancet. 2023. PMID: 36739136 Clinical Trial.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
Mast cells and cancer.
Paolino G, Corsetti P, Moliterni E, Corsetti S, Didona D, Albanesi M, Mattozzi C, Lido P, Calvieri S. Paolino G, et al. Among authors: corsetti s. G Ital Dermatol Venereol. 2019 Dec;154(6):650-668. doi: 10.23736/S0392-0488.17.05818-7. Epub 2017 Nov 30. G Ital Dermatol Venereol. 2019. PMID: 29192477 Free article. Review.
Light sheet fluorescence microscopy for neuroscience.
Corsetti S, Gunn-Moore F, Dholakia K. Corsetti S, et al. J Neurosci Methods. 2019 May 1;319:16-27. doi: 10.1016/j.jneumeth.2018.07.011. Epub 2018 Jul 23. J Neurosci Methods. 2019. PMID: 30048674 Review.
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure.
Roncato R, Peruzzi E, Gerratana L, Posocco B, Nuzzo S, Montico M, Orleni M, Corsetti S, Bartoletti M, Gagno S, Canil G, De Mattia E, Angelini J, Baraldo M, Puglisi F, Cecchin E, Toffoli G. Roncato R, et al. Among authors: corsetti s. Biomed Pharmacother. 2023 Aug;164:114906. doi: 10.1016/j.biopha.2023.114906. Epub 2023 Jun 7. Biomed Pharmacother. 2023. PMID: 37295250 Free article.
The United States COVID-19 Forecast Hub dataset.
Cramer EY, Huang Y, Wang Y, Ray EL, Cornell M, Bracher J, Brennen A, Rivadeneira AJC, Gerding A, House K, Jayawardena D, Kanji AH, Khandelwal A, Le K, Mody V, Mody V, Niemi J, Stark A, Shah A, Wattanchit N, Zorn MW, Reich NG; US COVID-19 Forecast Hub Consortium. Cramer EY, et al. Sci Data. 2022 Aug 1;9(1):462. doi: 10.1038/s41597-022-01517-w. Sci Data. 2022. PMID: 35915104 Free PMC article.
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer.
Peruzzi E, Gerratana L, Montico M, Posocco B, Corsetti S, Bartoletti M, Gagno S, Orleni M, De Mattia E, Baraldo M, Cecchin E, Puglisi F, Toffoli G, Roncato R. Peruzzi E, et al. Among authors: corsetti s. Biomed Pharmacother. 2023 Nov;167:115479. doi: 10.1016/j.biopha.2023.115479. Epub 2023 Sep 19. Biomed Pharmacother. 2023. PMID: 37734262 Free article.
Recent advances in the adjuvant treatment of early breast cancer.
De Luca C, Vici P, Carpano S, Sergi D, Viola G, Corsetti S, Toglia G, Pinnarò P, Vizza E, Amodio A, Paoletti G, Lopez M. De Luca C, et al. Among authors: corsetti s. Clin Ter. 2009;160(4):299-306. Clin Ter. 2009. PMID: 19795084 Review.
37 results